Based on virtual screening experiments by our molecular design lab, the first-in-class potent new small molecule inhibitor for disrupting the interaction of Thymic Stromal Lymphopoietin (TSLP) with its receptor. Characterization by the Hedtrich lab showed that this approach lowers TSLP-induced cytokine levels effectively and thus opens new perspectives for the treatment of atopic dermatitis. 

Link to the paper: Disrupting TSLP–TSLP receptor interactions via small molecule inhibitors yields a novel and efficient treatment option for atopic diseases